Aldeyra Therapeutics Inc. diskutieren
Aldeyra Therapeutics Inc.
WKN: A111X8 / Name: Aldeyra / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
folgen
a +
ALDEYRA THERAPEUTICS, INC. Healthcare | Biotechnologie | USA
hat $
Aldeyra multiple trials are set to read out in the second half of the year
Convincing data has been generated to date, and multiple trials are set to read out in the second half of the year, which will likely lead to a run-up.
Key points to the original bullish thesis included the following:
- The valuation of the company paled in comparison to the sheer size of the opportunity being targeted in the Dry Eye Disease market ($1.8 billion in prescription sales in 2016). The lengths that Allergan (NYSE:AGN) went to try to protect IP for its blockbuster eye treatment Restasis was proof enough of how valuable the DED market is.
- Topical ocular candidate ADX-102 generated encouraging data in a mid-stage study in patients with dry eye disease, with significant improvements recorded across a variety of measures (high statistical significance). Improvements in signs and symptoms of the disease were clear within the first week of therapy and a dose response was observed, with activity increasing throughout the time patients were being treated.
- A potential point of differentiation as compared to other approved dry eye treatments was that ADX-102 reduced levels of pro-inflammatory aldehyde mediator malondialdehyde in patients' tears.
- Lastly, there was more to this story than dry eye disease, as a pivotal study of ADX-102 in allergic conjunctivitis was in the works following feedback from regulatory agencies. The drug could address an adequate response to antihistamines, which affects around one-third of allergic conjunctivitis patients (worldwide prevalence of 20% to 40% of population). Also, results from its phase 3 program in noninfectious anterior uveitis were expected in the second half of 2018 along with preliminary results from a pivotal study in Sjögren-Larsson Syndrome (no FDA approved therapies for the latter).
Biotechnologie und medizinische SecteurRecherche
Aldeyra Therapeutics, Inc. ist ein Biotechnologie - Unternehmen.
Es konzentriert sich in erster Linie auf der Entwicklung neuer Produkte für Immun-, Entzündungs-, Waisen und andere , die als freie Aldehyde bekannt durch natürliche toxische chemische Spezies teilweise verursacht werden , zu denken.
Das Unternehmen wurde von Thomas A. Jordan und John E. Dowling August 2004 13, gegründet und ist in Lexington, MA ansässig.
Anzahl der Mitarbeiter: 11 Personen.
SecteurRecherche biotechnologique et médicale Agenda 07/08 Publication de résultats
Aldeyra Therapeutics, Inc. est une société de biotechnologie.
Il se concentre principalement sur le développement de nouveaux produits pour les maladies immunitaires, inflammatoires, orphelines et autres.
La société a été fondée par Thomas A. Jordan et John E. Dowling le 13 août 2004 et son siège est à Lexington, MA.
Nombre d'employés : 12 personnes.
marge stimmt der Buy-Einschätzung von stratec zu
marge stimmt am 28.09.2018 der Buy-Einschätzung von stratec mit dem Kursziel 19$ zu.
Überschrift: Aldeyra multiple trials are set to read out in the second half of the year
Hoffnungsvoller
Chart
Neueinstieg
nach Stopploss.
Recherche biotechnologique et médicale Agenda 04/06 Assemblée générale
Nombre d'employés
: 12 personnes.
Geht
hier bald was?
Boden
bei 6?
Geht
es weiter bergab?
Neueste Beiträge
fenjal in Hitachi Ltd. diskutieren